--- title: "MapLight Therapeutics Sets Q3 2026 for Phase 2 Trial Results in Schizophrenia and Autism" description: "MapLight Therapeutics Inc. has announced that topline results for its Phase 2 clinical trials, ZEPHYR and IRIS, are expected in Q3 2026. The ZEPHYR trial focuses on ML-007C-MA for schizophrenia, invol" type: "news" locale: "en" url: "https://longbridge.com/en/news/272071336.md" published_at: "2026-01-09T12:00:14.000Z" --- # MapLight Therapeutics Sets Q3 2026 for Phase 2 Trial Results in Schizophrenia and Autism > MapLight Therapeutics Inc. has announced that topline results for its Phase 2 clinical trials, ZEPHYR and IRIS, are expected in Q3 2026. The ZEPHYR trial focuses on ML-007C-MA for schizophrenia, involving 300 hospitalized adults with acute psychosis. The IRIS trial evaluates ML-004 for autism spectrum disorder, with around 160 participants. Results from both studies have not yet been presented. MapLight Therapeutics Inc. announced updates on the expected timing of topline results for its ongoing Phase 2 clinical studies. The ZEPHYR trial, evaluating ML-007C-MA for the treatment of schizophrenia, is a randomized, double-blind, placebo-controlled study enrolling 300 hospitalized adult participants experiencing acute exacerbation of psychosis. Topline results for this trial are now expected in the third quarter of 2026. Additionally, the IRIS trial, a double-blind, placebo-controlled Phase 2 study of ML-004 in autism spectrum disorder with approximately 160 adult and adolescent participants, is also expected to report topline results in the third quarter of 2026. Results from both studies have not yet been presented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622764-en) on January 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) ### Related Stocks - [MPLT.US - MapLight Therapeutics](https://longbridge.com/en/quote/MPLT.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 董事 Robert C. Malenka 報告出售 Maplight Therapeutics Inc.的普通股 | 羅伯特·C·馬倫卡（Robert C. Malenka），Maplight Therapeutics Inc. 的董事，已報告出售該公司的普通股。完整的文件可通過提供的鏈接獲取。此新聞簡報由公共技術公司生成，僅供信息參考，不應被視為財務、投 | [Link](https://longbridge.com/en/news/274900553.md) | | 董事 Robert C. Malenka 報告了出售 MapLight Therapeutics Inc.普通股 | 羅伯特·C·馬倫卡董事報告了對 Maplight Therapeutics Inc.普通股的處置。完整的文件可以通過提供的鏈接訪問。此消息由公共技術公司（PUBT）生成，僅供信息參考，不構成財務或法律建議。原始內容由 Maplight Th | [Link](https://longbridge.com/en/news/274371236.md) | | 美團 (3690) 盈警，料去年度業績由盈轉虧 | 美團近日發出盈警，預計 2025 年度將錄得虧損 233 億至 243 億元人民幣，較 2024 年盈利 358 億元大幅惡化。虧損主要源於核心本地商業分部的經營虧損及對海外業務的加大投入。美團已加大對生態體系的投入以應對激烈競爭，包括強化 | [Link](https://longbridge.com/en/news/276027930.md) | | NCCN 發佈的新指南詳細闡述了兒童癌症與成人癌症之間的基本差異 | 國家綜合癌症網絡（NCCN）發佈了針對兒童軟組織肉瘤的新臨牀實踐指南，重點關注橫紋肌肉瘤（RMS），這是兒童中最常見的軟組織肉瘤。這些指南提供了基於證據的診斷、治療和風險分層建議，強調了兒童癌症與成人癌症之間的差異。其目的是確保有效治療的同 | [Link](https://longbridge.com/en/news/276145789.md) | | 關鍵的 Vopimetostat 胰腺癌試驗計劃可能會改變投資 Tango Therapeutics (TNGX) 的理由 | Tango Therapeutics, Inc. 正在推進 vopimetostat 進入一項針對第二線胰腺癌的關鍵性 300 名患者的臨牀試驗，此舉是在與 FDA 進行積極互動後進行的。儘管公司目前處於虧損狀態且面臨高風險的腫瘤學試驗，但 | [Link](https://longbridge.com/en/news/276141096.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.